Disease · MONDO_0005280

prostatitis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. prostatitis. Diseases, record MONDO_0005280. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005280

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: prostatitis; Open Targets
Open Targets ID: MONDO_0005280; Open Targets
Other names: Acute Bacterial Prostatitides, Acute Bacterial Prostatitis, Asymptomatic Inflammatory Prostatitides, Asymptomatic Inflammatory Prostatitis, Bacterial Prostatitides, Acute, Bacterial Prostatitides, Chronic, Bacterial Prostatitis, Acute, Bacterial Prostatitis, Chronic, Chronic Bacterial Prostatitides, Chronic Bacterial Prostatitis, Chronic Prostatitis with Chronic Pelvic Pain Syndrome, Inflammatory Prostatitis, Asymptomatic, Prostatitides, Prostatitides, Chronic Bacterial, inflammation of prostate gland, prostate gland inflammation, prostatitis (disease); Open Targets
Disease Ontology: DOID:14654; Disease Ontology
MeSH: D011472; MeSH
NCI Thesaurus: C26866; NCI Thesaurus
Highest stage of its drugs: Approval, for 5 of its 15 drugs, from DailyMed and TTD; Open Targets

Drugs15

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CIPROFLOXACIN	CHEMBL8	Small molecule	Approval	DailyMed	2	1	1	Drugs and targets
CEFAZOLIN SODIUM	CHEMBL1200523	Small molecule	Approval	DailyMed	21	0	0	Drugs and targets
CEPHALEXIN	CHEMBL1200544	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
FLAVOXATE HYDROCHLORIDE	CHEMBL1200875	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
PLAZOMICIN	CHEMBL1650559	Small molecule	Approval	TTD	1	0	0	Drugs and targets
LEVOFLOXACIN	CHEMBL5315124	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
PRULIFLOXACIN	CHEMBL422648	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
ROSIPTOR	CHEMBL3989954	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
TAMSULOSIN	CHEMBL836	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
TANEZUMAB	CHEMBL2108567	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 15

See all 15 drugs

Targets15

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ADRA1A	Adrenergic receptor alpha-1	1	Adrenergic receptor alpha-1 antagonist	Phase 2	https://conductscience.org/library/genes/148	Drugs and targets
ADRA1B	Adrenergic receptor alpha-1	1	Adrenergic receptor alpha-1 antagonist	Phase 2	https://conductscience.org/library/genes/147	Drugs and targets
ADRA1D	Adrenergic receptor alpha-1	1	Adrenergic receptor alpha-1 antagonist	Phase 2	https://conductscience.org/library/genes/146	Drugs and targets
GNRHR	Gonadotropin-releasing hormone receptor	1	Gonadotropin-releasing hormone receptor antagonist	Phase 2	https://conductscience.org/library/genes/2798	Drugs and targets
INPP5D	Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 1	1	Phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase 1 activator	Phase 2	https://conductscience.org/library/genes/3635	Drugs and targets
NGF	Beta-nerve growth factor	1	Beta-nerve growth factor inhibitor	Phase 2	https://conductscience.org/library/genes/4803	Drugs and targets
PDE4A	Phosphodiesterase 4	1	Phosphodiesterase 4 inhibitor	Approval	https://conductscience.org/library/genes/5141	Drugs and targets
PDE4B	Phosphodiesterase 4	1	Phosphodiesterase 4 inhibitor	Approval	https://conductscience.org/library/genes/5142	Drugs and targets
PDE4C	Phosphodiesterase 4	1	Phosphodiesterase 4 inhibitor	Approval	https://conductscience.org/library/genes/5143	Drugs and targets
PDE4D	Phosphodiesterase 4	1	Phosphodiesterase 4 inhibitor	Approval	https://conductscience.org/library/genes/5144	Drugs and targets

1 to 10 of 15

See all 15 targets

Trials5

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00826514	An Efficacy And Safety Study Of Tanezumab For The Treatment Of Pain Associated With Chronic Abacterial Prostatitis	Phase 2	62	2021-05-13	Chronic Prostatitis With Chronic Pelvic Pain Syndrome	TANEZUMAB	Its record names the disease	ClinicalTrials.gov
NCT03500159	Efficacy and Safety of AQX-1125 in Subjects With Chronic Prostatitis/Chronic Pelvic Pain Syndrome	Phase 2	3	2019-01-09	Chronic Prostatitis, Chronic Pelvic Pain Syndrome	ROSIPTOR	Open Targets' reading of its record	ClinicalTrials.gov
NCT04552431	Chronic Prostatitis Collaborative Research Network Clinical Trial- Ciprofloxacin and Tamsulosin	Phase 2	196		Chronic Prostatitis With Chronic Pelvic Pain Syndrome	CIPROFLOXACIN, TAMSULOSIN	Its record names the disease	ClinicalTrials.gov
NCT03201796	Prulifloxacin in Chronic Bacterial Prostatitis (CBP)	Phase 2	168		Chronic Bacterial Prostatitis	PRULIFLOXACIN	Its record names the disease	ClinicalTrials.gov
NCT00277511	Levofloxacin, Chronic Bacterial Prostatitis	Phase 3	120		Prostatitis	LEVOFLOXACIN	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials4

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Tanezumab vs Placebo: Number of Participants With Clinically Significant Neurological Examination Abnormalities	3 of 30	1 of 32	62	NCT00826514	Trial comparisons
Tanezumab vs Placebo: serious adverse events	1 of 30	0 of 32	62	NCT00826514	Trial comparisons
AQX-1125 vs Placebo: deaths from any cause	0 of 2	0 of 1	3	NCT03500159	Trial comparisons
AQX-1125 vs Placebo: serious adverse events	0 of 2	0 of 1	3	NCT03500159	Trial comparisons

Papers from its trials0

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

None in this release.

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005280

GET https://conductscience.org/api/diseases/v1/MONDO_0005280/drugs

API reference For AI assistants